Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Chen C, Siegel D, Gutierrez M, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and waldenstrom macroglobulinemia. Blood. 2018;131(8):855–863. doi:10.1182/blood-2017-08-797886
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132(24):2546–2554. doi:10.1182/blood-2018-06-858852
   PubMed Web of Science ®Google Scholar
• Syed YY. Selinexor: first global approval. Drugs. 2019;79(13):1485–1494. doi:10.1007/s40265-019-01188-9
   PubMed Web of Science ®Google Scholar
• Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(9):859–866. doi:10.1200/JCO.2017.75.5207
   PubMed Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. doi:10.1056/NEJMoa1903455
   PubMed Web of Science ®Google Scholar
• US-FDA. FDA grants accelerated approval to selinexor for multiple myeloma. 2019. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-selinexor-multiple-myeloma. Accessed December, 2020.
   Google Scholar
• Walker JS, Garzon R, Lapalombella R. Selinexor for advanced hematologic malignancies. Leuk Lymphoma. 2020;61(10):2335–2350.
   PubMed Web of Science ®Google Scholar
• Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, Phase 3 trial. Lancet. 2020;396(10262):1563–1573. doi:10.1016/S0140-6736(20)32292-3
   PubMed Web of Science ®Google Scholar
• Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E. Clinical utility of selinexor/dexamethasone in patients with relapsed or refractory multiple myeloma: a review of current evidence and patient selection. Onco Targets Ther. 2020;13:6405–6416. doi:10.2147/OTT.S227166
   PubMed Web of Science ®Google Scholar
• Abramson HN. B-Cell Maturation Antigen (BCMA) as a target for new drug development in relapsed and/or refractory multiple myeloma. Int J Mol Sci. 2020;21(15):5192. doi:10.3390/ijms21155192
   Web of Science ®Google Scholar
• Cho SF, Lin L, Xing L, et al. BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma. Cancers. 2020;12(6):1–29. doi:10.3390/cancers12061473
   Web of Science ®Google Scholar
• US-FDA. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Accessed November 25, 2020.
   Google Scholar
• Markham AJD. Belantamab mafodotin: first approval. Drugs. 2020;1–7. doi:10.1007/s40265-019-01241-7
   Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase 2 study. Lancet Oncol. 2020;21(2):207–221. doi:10.1016/S1470-2045(19)30788-0
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion Phase 1 trial. Lancet Oncol. 2018;19(12):1641–1653. doi:10.1016/S1470-2045(18)30576-X
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37. doi:10.1038/s41408-019-0196-6
   PubMed Web of Science ®Google Scholar
• Trudel S, Cohen AD, Richardson PG, et al. Safety and tolerability of single-agent belantamab mafodotin in heavily pre-treated patients with relapsed/refractory multiple myeloma: pooled data from DREAMM-1 and DREAMM-2. HemaSphere. 2020;4:429–430.
   Google Scholar
• Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 Study. Ophthalmol Ther. 2020;9(4):889–911.
   PubMed Web of Science ®Google Scholar
• Razak ARA, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Jasielec JK, Rosenbaum CA, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019;186(4):549–560. doi:10.1111/bjh.15969
   PubMed Web of Science ®Google Scholar
• Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–142. doi:10.1056/NEJMoa1515725
   PubMed Web of Science ®Google Scholar
• Bahlis N, Chen C, Sebag M, et al. A phase 1B/2 study of selinexor in combination with backcone therapies for treatment of relapsed/refactory multiple myeloma. Haematologica Conf. 2016;101:84.
   Web of Science ®Google Scholar
• Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;2013(3):Cd004310.
   Google Scholar
• Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567–573. doi:10.1200/JCO.2002.20.2.567
   PubMed Web of Science ®Google Scholar
• Chen CI, Bahlis N, Gasparetto C, et al. Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Blood. 2019;134.
   Web of Science ®Google Scholar
• Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):e447–e460. doi:10.1016/S1470-2045(14)70006-3
   PubMed Web of Science ®Google Scholar
• Sun JX, Yang N. Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy? Asia Pac J Clin Oncol. 2014;10(2):e108–e113. doi:10.1111/ajco.12055
   Web of Science ®Google Scholar
• Hovan AJ, Williams PM, Stevenson-Moore P, et al. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer. 2010;18(8):1081–1087. doi:10.1007/s00520-010-0902-1
   PubMed Web of Science ®Google Scholar
• Park SE, Hwang JH, Choi JH, et al. Incidence, risk factors, and clinical outcomes of acute kidney injury caused by palliative chemotherapy in lung cancer. J Cancer. 2019;10(22):5332–5338. doi:10.7150/jca.28399
   Web of Science ®Google Scholar
• Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody–drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604. doi:10.1089/jop.2015.0064
   PubMed Web of Science ®Google Scholar
• Fathi AT, Chen R, Trippett TM, et al. Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. Washington, DC: American Society of Hematology; 2014.
   Google Scholar
• Moskowitz CH, Forero-Torres A, Shah BD, et al. Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. Washington, DC: American Society of Hematology; 2014.
   Google Scholar
• Eliason L, Opalinska J, Martin ML, et al. Dreamm-1: patient perspectives from the first-in-human study of single-agent belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM). HemaSphere. 2020;4:936.
   Google Scholar
• Popat R, Warcel D, O’Nions J, et al. Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 2020;105(5):e261. doi:10.3324/haematol.2019.235937
   PubMed Web of Science ®Google Scholar
• Accessdata.fda.gov. BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use. 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf. Accessed February 1, 2021.
   Google Scholar
• Goldschmidt H, Ashcroft J, Szabo Z, Garderet L. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol. 2019;98(1):1–18. doi:10.1007/s00277-018-3546-8
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275. doi:10.1038/s41375-019-0435-7
   PubMed Web of Science ®Google Scholar
• Machlus KR, Wu SK, Vijey P, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017;130(9):1132–1143. doi:10.1182/blood-2016-11-752840
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020;34(9):2430–2440. doi:10.1038/s41375-020-0756-6
   PubMed Web of Science ®Google Scholar